Gen­Fleet high­lights Phase 2 da­ta on KRAS/EGFR com­bo in lung can­cer 

As com­pa­nies in­creas­ing­ly look to com­bi­na­tions to boost the ef­fi­ca­cy of KRAS ther­a­pies, a Phase 2 study is of­fer­ing some of the first clin­i­cal ev­i­dence …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER